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PEMBANGUNAN DAN PENILAIAN TABLET PELEPASAN TERPANJANG 
KETOPROFEN 
ABSTRAK 
\ > 
Suatu sistem perlepasan terpanjang telah dibangunkan menggunakan salutan 
filem sebagai sistem perlepasan terpanjang drug dan ketoprofen telah 
digunakan sebagai drug model. Drug berkenaan telah disediakan dalam bentuk 
tablet yang mengandungi 15% Gelucire 50113 sebagai bahan pembentuk 
matriks. Kemudian ia disalut secara berfilem dengan etilselulosa (300cps). 
Keputusan ujian fizikal yang dijalankan ke atas rumusan-rumusan yang dikaji 
adalah memuaskan. Kajian kelarutan in vitro menunjukkan bahawa ketebalan 
salutan setebal 0.04 mm adalah cukup untuk mengekalkan kadar pembebasan 
ketoprofen sehingga 8 jam, yang mana ia adalah setanding dengan sediaan 
rujukan komersil (Oruvail CR 100 mg) daripada segi profil pembebasan dan 
jumlah pembebasan ubat. Pengekalan kadar pembebasan sehingga 12 jam 
juga dicapai dengan ketebalan salutan setebal 0.06 mm. Kadar pembebasan 
ubat adalah stabil dalam tempoh enam bulan pertama semasa proses penuaan 
pada 25°C iaitu pada suhu bilik tetapi pembebasan telah menurun sedikit 
selepas enam bulan proses penuaan yang berikutnya. Kadar pembebasan ubat 
adalah pada dasamya tidak bergantung kepada kesan permatangan. 
Kajian terma ke atas ketoprofen dengan setiap eksipien individu dalam nisbah 
campuran 1: 1 menunjukkan ciri-ciri endotermik ketoprofen menurun dengan 
Gelucire 50/13, PVP (K30) dan magnesium stearat. lni disebabkan oleh 
berlakunya kehilangan air (dehidrasi), manakala tidak terdapat perubahan pada 
takat cair ketoprofen dengan etilselulosa dan laktosa. Ketidakhadiran ciri-ciri 
xviii 
endotermik ketoprofen di dalam tablet menunjukkan wujudnya interaksi yang 
kuat tetapi tidak semestinya disebabkan oleh ketidaksesuaian. 
'.' 
Kajian FTIR menunjukkan kumpulan-kumpulan berfungsi pada ketoprofen 
adalah stabil dan tidak mempunyai interaksi dengan mana-mana eksipien sama 
ada dalam bentuk campuran fizikal ataupun tablet. 
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DEVELOPMENT AND EVALUATION OF PROLONGED RELEASE 
KETOPROFEN TABLETS 
ABSTRACT 
A prolonged release system was developed using film coating as drug release 
controlling system and ketoprofen as model drug. The drug was prepared in 
tablets containing 15% Gelucire 50/13 as matrix forming material, and then the 
tablets were film coated with ethylcellulose (300cps). The results of physical 
tests for the formulations and the coating materials were satisfactory. The in 
vitro dissolution studies showed that the rate of ketoprofen release was 
sufficiently sustained for up to 8 hours with coating thickness 0.04 mm, and this 
was found to be comparable with the commercial reference preparation (Oruvail 
CR 1 00 mg) in terms of the release profile and extent of drug release. A 12 
hours sustained release profile was achieved with coating thickness 0.06 mm. 
The rate of drug release was stable for the first six months of ageing at room 
temperature 25°C, but the release was slightly decreased in the next six months 
of ageing. The rate of drug release was essentially independent of the curing 
effect. 
Thermal study of ketoprofen with each individual excipient at a ratio of 1:1 
showed that ketoprofen decreased in its melting endothermic characteristics 
with Gelucire 50/13, PVP (K30) and magnesium stearate, which was due to the 
loss of water (dehydration), while there was no changes in the melting point of 
ketoprofen with ethylcellulose and lactose. The absence of the melting 
endothermic characteristics of ketoprofen in the tablet indicates a strong 
interaction but not necessarily of incompatibility. 
)()( 
The FTIR studies showed that the ketoprofen functional groups were stable and 
did not have any interactions with any excipients in the form of physical mixture 
as well as in the form of tablet. 
\· 
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CHAPTER 1 
INTRODUCTION 
'.. 
1.1 Oral prolonged release dosage forms 
Oral administration is the preferred delivery route for various modes of introducing 
a drug into the body, because it is simple, easy and convenient method of drug 
administration. Ideally, an oral dosage form should deliver the drug at a specified 
rate, for a specific period of time and even at a designated location (Juliano, 1980; 
Szycher, 1991). Blood is usually the medium of transport for the absorbed drug, 
thus, the ideal plasma concentration levels which produces optimal therapeutic 
activity must be obtained. However, these drug delivery targets could only be 
achieved in part through conventional dosage form (Lee and Good, 1987). 
Conventional drug delivery systems are designed to release their content promptly 
for absorption, thus giving a maximum rate and extent of absorption. Hence, wide 
fluctuations in peak and through steady-state drug levels are frequently obtained 
with these products, particularly for drugs having short biological half-life. By 
increasing the frequency of dosing, it may be possible to reduce such undesirable 
fluctuations particularly with drugs with narrow therapeutic indices. However this 
may lead to patient inconvenience and poor compliance. In order to overcome this 
problem, various sustained release formulations have been widely developed to 
improve the therapeutic performance of drugs, in particular, to increase 
pharmacological efficacy and reduce side effects (Pather et a/., 1998; Sanchez-
1 
Lafuente eta/., 2002; Kramar eta/., 2003) To be effective such formulations must 
control the rate of oral drug release for absorption over an extended period of time 
after each administration. 
\ . 
As mentioned in British Pharmacopoeia (BP 2005), modified release dosage forms 
include prolonged release, delayed release and pulsatile release dosage forms. 
Therefore, the terms controlled release and sustained release were included under 
prolonged release. Prolonged release dosage forms show a slower release of the 
active substance(s) than that of a conventional release dosage forms. The 
prolonged release dosage form should be tailored so that variations in components 
lead to predictable alterations in released profiles. Controlled release (CR) systems 
are designed to deliver drugs at a predetermined rate and even at a desired 
location, in order to maintain relative constant drug levels n plasma for an extended 
period of time (Juliano, 1980; Szycher, 1991; Hashida, 1998). These systems can 
offer less fluctuation in plasma drug level so that adverse effects could be reduced 
due to more uniform drug levels. In addition, they could also achieve reduction in 
the cost for overall treatment and in the frequency of drug administration, hence, 
leading to improved patient compliance (Lordi, 1986; Khan et a/., 1995). 
Ketoprofen is a very good candidate for formulation of controlled release dosage 
forms (Habib and Mesue, 1995; Parejo eta/., 1998; Palmieri eta/., 2002), due to 
the short half-life (Reynolds, 1996), low bioavailability and local or systemic 
disturbance in the Gl tract (Liversidge, 1981) which could lead to withdrawal of 
treatment. 
2 
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1.1.1 Methods of achieving oral prolonged release dosage form 
A number of techniques have been used to achieve oral prolonged drug delivery, 
since it provides many advantages .. These advantages include more predictable 
\' 
gastric emptying (Davis, 1986), minimizing local concentration of drug (Eskilson, 
1985), less likelihood of dose dumping (Sam, 1985) and lower incidence of inter-
and intrasubject variability (Kyroudis et a/., 1989; Butler et a/., 1998). In general, 
prolonged release formulations can be divided into different categories based on 
the methods of preparation and I or the mechanisms of drug release, which will be 
discussed in the following sections {Lordi, 1986). The methods can be divided into 
, .. 
four main categories, namely matrices system, coating or barrier membrane, 
osmotic pressure and ion-exchange resins. The choice of method for achieving 
prolonged release in a particular application depends on a number of factors such 
as the cost, the potency and the properties of the agent, the environmental issues 
of use and any requirement for biodegradability. 
1.1.1 (a) Matrices system 
Matrices type or diffusion prolonged dosage forms by using polymeric excipients 
have been widely utilized to control the release rate of various type of drugs 
(Hogan, 1989), in which the drug is uniformly dissolved or dispersed throughout the 
polymer mass. The release pattern depends on the geometry of the system, the 
identity and nature of the polymer or other carrier material. For those drugs with 
rapid dissolution, embedding them within slowly dissolving or erodible matrices 
provides a way of retarding the dissolution rate. Most of the oral matrices 
prolonged release products utilize either hydrophilic or hydrophobic matrices 
3 
systems in which the drug is homogeneously distributed or dissolved in the 
polymeric matrices. 
',' 
The matrix system is commonly used for manufacturing sustained release dosage 
forms because it makes such manufacturing easy. One of the most common 
approaches used to achieve sustained release is to incorporate a drug in a 
hydrophobic matrix such as wax, polyethylene, polypropylene, Gelucire and 
ethylcellulose or a hydrophilic matrix such as carboxymethylcellulose, 
hydroxypropylmethylcellulose and methylcellulose (Sriwongjanya and Bodmeier, 
1998). 
It is necessary to have some knowledge of the material properties of the devices in 
order to predict the kinetics of drug release, so controlled release mechanisms 
have been described, including diffusion through matrices or across membranes 
and erosion mechanism. A simple semi-empirical equation was put forward to 
describe the drug release behavior from a hydrophilic matrices system (Peppas, 
1985; Ford eta/., 1991) while the release from a hydrophobic monolithic matrices 
system that resulted in the square-root of time release profile had been described 
previously by Higuchi (1963). Hydrophilic matrices have become most popular as 
modified release dosage form for oral administration. Hydrophilic matrices consist 
of materials that swell and form gels upon contact with water or gastrointestinal 
fluids. Drug release in such system is controlled by the leaching/diffusion of the 
active substances through the swollen hydrates matrices, as well as due to the 
4 
erosion of the gelled layer (Peppas, 1985). Hydrogel is an important class of the 
hydrophilic matrices former, which is capable of swelling in water and retaining a 
considerable amount of water without dissplving in it (Breimer eta/., 1985). 
\' 
1.1.1 (b) Coating I Barrier membrane 
Polymeric coating techniques have been widely applied in pharmaceutical industry 
for many reasons such as taste masking, stability improvement, protective barrier, 
and especially for the controlled release of drugs for the preparation of various 
dosage forms (McGinity, 1989). In general, coating dispersions are applied on 
various drug-loaded cores such as seed, pellet, bead, granule or tablet. Today, 
films have earned an important place in controlled release drug delivery systems. 
Many of these systems are tablets or capsules (matrices) covered with a film that 
helps in achieving the controlled release of a drug. Various materials have been 
used for the preparation of these systems, in which ethylcellulose is one of the 
most widely used hydrophobic polymer (Donbrow and Friedman, 1974; Palmieri 
and Wehrle, 1997; Lin eta/., 2001; Ymada eta/., 2001). Some important criteria, 
such as drug release from a system were explained by studies _conducted on films 
or membranes. Often, tablets coated with a film behave differently from the film 
itself. However, there is no doubt that studies conducted on films help in 
understanding the behavior of tablets coated with these films. Various properties 
have been studied in detail such as drug release, dry and wet strengths, effect of 
plasticizers and adhesion to tablet surfaces (Rowe, 1986; Bodmeier and 
Paeratakul, 1990, 1993; Bechard et.al., 1995; Lehtola eta/., 1995; Okutgen eta/., 
1995). 
5 
Enteric coated dosage forms are designed to resist the acidic environment of the 
stomach and disintegrate in the higher pH environment of the intestinal fluid. It 
controls the rate of drug release by s~elling in water and forming a permeable 
',' 
membrane. The reasons for using an enteric coating are to protect the stomach 
wall from the effect of the drug contents in a dosage form and/or to protect the drug 
contents in a dosage from the harmful effect of the gastric contents. Enteric coating 
can also be used to deliver the active ingredients to a particular region of the 
intestine, e.g. the upper part of the small intestine, so as to enhance the 
bioavailability of the drug (Leopold, 1999). 
The film coating membrane for conventional dosage form should have good 
solubility in aqueous fluid to facilitate the dissolution of the active ingredient, while 
modified release action requires a polymer system with low water solubility or 
permeable membrane. In this latter system the release rate of drug is determined 
by its diffusion through a water insoluble membrane. Th~ uniformity of tablet 
coating is very important as it affects the organoleptic quality of tablets and 
functionality of the coating, especially in the case of modified release formulations. 
The rate of drug release depends upon the thickness of the coated film (Fourman 
eta/., 1995), and/or the porosity of the coating membrane. Rowe (1985) reported 
that the ethylcellulose with hydroxypropyl methylcellulose are widely used in the 
formulation of delayed or sustained drug release film coatings. The water insoluble 
ethylcellulose is usually chosen as the coating material and the water soluble 
hydroxypropylmethylcellulose as ~he minor component. The drug is released 
through pores created in the film coating by the dissolution of the dispersed phase. 
6 
The use of amylose-ethylcellulose film coatings as oral colon specific drug delivery 
system has been also reported by Lee eta/. (2000). 
\' 
1.1.1 (c) Osmotic pumps 
osmotic systems for controlled drug-delivery applications are well established and 
suitable for oral administration. Osmotic pumps for controlling the drug release are 
unique, dynamic and widely employed in clinical practice (Santus and Baker, 1995; 
Singh et a/., 1999). The device consists of an outside layer of semi permeable 
membrane coating a compressed core which has a mixture of drug and osmotic 
agent. When the device is placed in water, osmotic pressure generated by the 
osmotic agent within the core causes water to move into the device, which forces 
the dissolved drug to move out of the delivery orifice. The absorption of the water 
by the core depends on the osmotic pressure generated by the core components 
and the semi permeable membrane. The release rate of the drug from an osmotic 
device is relatively unaffected by the pH and hydrodynamics of the external 
dissolution medium. Osmotic systems are appropriate to drugs with a broad range 
of aqueous solubilities. Depending on the aqueous solubility, the drug is released 
either as a solution or as a suspension. The in vivo rate of drug release from 
osmotic device is comparable to the in vitro rate, producing an excellent in vitro/in 
vivo correlation (Thombre eta/., 2004). 
The osmotic preparation can be designed as single unit tablets with single orifice, 
so the drug solution can flow through it. This single orifice formed in the membrane 
by boring with a laser beam. Osmotic system can be also designed as multiple 
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units tablet in which the drug solution can flow through a number of pores formed 
during the uptake of water (Aulton, 2002). 
'.' 
oue to some reasons osmotic systems can be to some extent complex to 
manufacture, such as, the tablet core components may have poor to marginal flow 
and compression characteristics, in most systems a laser drilling process is 
needed to form the delivery port(s) and a solvent based process is used to apply 
the semi permeable membrane coating onto the tablet cores. Even if there are 
some manufacturing complexity, osmotic drug-delivery systems have been 
successfully used in many commercial products (Thombre eta/., 2004). 
In the middle of 1970s, Theeuwes eta/. (1975) developed an elementary osmotic 
pump to achieve controlled drug delivery. The delivery of the drug from the system 
is controlled by solvent influx across a semipermeable membrane, which in turn 
carries the drug outside through a laser drilled orifice. The osmotic and hydrostatic 
pressure differences on either side of the semipermeable membrane govern fluid 
transport into the system. Osmotic system has been applied to deliver drugs such 
as testosterone (Kazuto et a/., 1999), diltiazem HCI (Prabakaran et a/., 2003) and 
pseudoephedrine (Sapna eta/., 2003). 
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1.1.1 (d) ton-Exchange Resins 
ton-exchange resins (IER), or ionic polymer networks {which is designed to provide 
controlled release for ionizable drugs), have been used for many years in 
\· 
pharmaceutical formulations. Jon exchange materials are insoluble substances 
containing loosely held ions which are able to be exchanged with other ions in 
solutions which come in contact with them. Jon exchange is the reversible 
interchange of ions (of like charge) between a liquid and a solid phase, involving no 
radical change in the structure and properties of the solid. The solid phases in the 
ion exchange process are referred to as IER, and are usually the polymers with 
integrated ionic moieties. Based on the nature of the ionic species being 
interchanged, ion exchange resins are insoluble polymers that contain acidic or 
basic functional groups which have salts which are also insoluble, and this enables 
them to exchange either positively charged ions (cation exchangers) such as 
amino or quaternary ammonium groups and negatively charged ones (anion 
exchangers) such as carboxylic groups, or sulfonic groups in repeating positions 
on the resin chain (Sriwongjanya and Bodmeier, 1998). These materials are totally 
insoluble in all solvents and at all pHs, combined with their ·large particle size 
means that they are not absorbed by the body, and so have proven to be non-toxic 
and very safe. A drug resin complex is formed by prolonged exposure of drug to 
the resin. 
Their uses range from simple excipients for tablet disintegration to the rate 
controlling function in prolonged rt:lease formulations. An added advantage is that 
the technique provides some protection for very bitter or irritating drugs. Recently, 
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the ion exchange approach has been combined with coating to obtain more 
effective sustained release product. Jon exchange resins for controlled drug 
delivery was adapted from analytical ard protein chemistry (Kogan et a/., 1991; 
\' 
Novic eta/., 2001). 
In practice, drug in an ionic form (usually in solution) is mixed with the appropriate 
IER to form a complex, known as resinate. The performance of resinate is 
governed by several factors, such as the pH and temperature of the drug solution, 
the molecular weight and charge intensity of the drug and IER, ionic strength of the 
drug solution, degree of cross linking and particle size of the IER and contact time 
between the drug species and the IER (Piaizier-Vercammen, 1992; Liu et a/., 
2001). The liberation of free-drug ions happened when resinate from the delivery 
system reaches the site of delivery, the exchange process is reverted. Therefore 
the ionic strength and pH at the site of delivery play a key role in the liberation of 
immobilized drug from the resinate. The presence of highly activated counter ions 
at the site will cause drug delivery at the desired target via the ion exchange 
process to be occurring, resulting in the exchange of ions and drug release. The 
IER devoid of drug is eliminated or biodegraded from or at the site of delivery (Hui 
eta/., 1987). 
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1.1.2 Advantages and disadvantages of oral prolonged release dosage forms 
oral prolonged release dosage forms offer advantages over conventional dosage 
forms that deliver all of the active agent over a short period of time, therefore these 
',' 
forms gained medical acceptance due to their ability to achieve better therapeutic 
effects. If the therapeutic levels of a drug are controlled and maintained for an 
extended period of time, the dosing frequency can thus be reduced to once or 
twice daily which in turn can lead to increased patient convenience, improved 
pharmacokinetic profiles and compliance (Urquhart, 2000). The incidence and 
severity of untoward systemic side effects related to high peak plasma drug 
concentration will also be reduced. A reduction in the total amount of drug 
administered over the period of treatment will be achieved. This contributes to the 
reduced incidence of systemic and local side effects. Also, prolonged release can 
improve treatment of many chronic illnesses where symptom breakthrough occurs 
if the plasma concentration of drug drops below the minimum effective 
concentration. prolonged release can also reduce the incidence and severity of 
untoward systemic side effects related to high peak plasma drug concentration. 
Through the combination of a reduction in dosing frequency and an optimization of 
the amount of drug entering systemic circulation, a controlled release formulation 
may increase the efficacy of the compound and may improve patient compliance 
(Theeuwes, 1983; Urquhart, 2000). Hence, a better disease management and 
reliable therapy can be achieved with controlled release dosage forms (Welling and 
Dobrinska, 1987). 
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Another important benefit is the elimination of local gastrointestinal irritation and 
erosion arising from exposure of gastric mucosa to high drug concentrations 
released from the conventional dosage ~orms (Levy and Hayes, 1960; Boroda et 
\ ' 
al., 1973). 
Moreover, in view of the constant delivery of drug, prolonged release systems 
require a smaller amount of drug to produce therapeutic blood level for a given 
duration. This, in turn, will improve the economics especially for drugs that are 
expensive and difficult to extract or to obtain. It is claimed that cost savings are 
made from the better disease management that can be achieved with controlled 
release products (Lachman eta/., 1986). 
However, prolonged release dosage forms have several potential disadvantages. 
They include cost, unpredictable and often poor in vitro and in vivo correlation, 
dose dumping, reduced potential for dosage adjustment and increased potential for 
first pass clearance. The removal of drug after administration is difficult with 
controlled release preparation if adverse effects are noted, also if the drug cannot 
be accommodated. The physician has less flexibility in adjusting dosage regimens 
(Lachman et a/., 1986). Nevertheless, the advantages and potential benefits with 
prolonged release dosage forms appear to outweigh the disadvantages, and the 
growing interest in design and development of prolonged release dosage forms 
makes them more likely to be preferred in future. 
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t:"aluation of prolonged release dosage forms 
1 In vitro evaluation 
ensure and promote better safety d~ug use by patients, it is necessary to 
Jish appropriate guidelines for the design and evaluation of drug dosage form. 
~·D!-1·~ .... -
in vitro characteristics and quality of the product is essential in the 
t~development and evaluation of dosage forms. For solid prolonged release dosage 
~~-, 
,; forms. drug release characterization is the most important among various in vitro 
: tests because the in vitro dissolution test can serve the purpose of providing 
[;necessary quality and process control, determining stability of the relevant release 
t' 
;?,characteristics of the product and facilitating certain regulatory determinations and 
f·, 
~/~ 
~judgments concerning minor formulation changes. Therefore the purpose of the in 
~!' 
vitro evaluation is to minimize or eliminate the risk of marketing an unsafe product, 
guaranteeing the efficacy of the product, which meets the regulatory requirements 
(Skelly eta/., 1993). 
Dissolution testing is the most important in vitro test. Dissolution studies are carried 
out to evaluate the potential effect of formulation and process variables on the 
' bioavailability of a drug, to ensure that preparations comply with product 
specifications and to indicate the performance of the preparation under in vivo 
conditions. However, the dissolution rate of a specific dosage form is essentially an 
arbitrary parameter that may vary with the dissolution methodology, such as type of 
apparatus, medium and agitation. Some of the attributes essential for a good in 
vitro dissolution are, the output sh<;>uld be reproducible and associated in some 
way with in vivo data, the system should be sufficiently sensitive in discriminating 
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between in vitro variables that may yield differences in vivo and the system should 
be flexible and have a wide range of application to products (Gupta and Robinson, 
1992). 
Basically most of the pharmaceutical solid and solid dispersion dosage forms 
undergo dissolution testing. The in vitro test conditions should have meaningful 
relationships to the conditions in gastrointestinal tract and should be a part of 
dissolution test methodology. There are several factors that affect the dissolution 
rate of drug dosage forms. The physicochemical properties of the drug substance 
play a prime role in controlling its dissolution from the dosage form (Wagner, 
1975). These include particle size, crystalline state such as polymorphism and 
state of hydration and also physical properties such as density and viscosity of the 
dissolution media affect the dissolution rate (Banakar, 1983). 
Several instruments and techniques have evolved in dissolution testing and are 
divided into two categories. These are the beaker methods and the flow through 
column system. Both are easy to operate and the procedure readily automated. 
The dissolution process and the design of the dissolution apparatus affect the 
dissolution rates through a number of factors. These include the geometry and 
design of the container, the intensity and type of agitation, composition, volume, 
and the temperature of the dissolution medium. These factors, in turn, affect the 
abrasion rate of the intact solid dosage form on the particles, the dispersion of the 
disintegrated particles, the hctnogeneity of the dissolution fluid and the 
reproducibility of the system from run to run (Shargel and Andrew, 1999). 
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1.3 Thermal analysis 
1.3.1 Introduction 
For a recent few decades, we have observed remarkable development in thennal 
\· 
analysis, especially in new techniques by which chemical and structural changes in 
the sample can be directly observed (Ozawa, 2000). Thermal analysis methods 
provide fundamental knowledge about the properties of polymers for processing 
and application. It comprises of a group of techniques in which a physical property 
of a substance is measured as a function of temperature, while the substance is 
subjected to a controlled temperature program (Wendlandt, 1974; Warne, 1992). In 
differential thermal analysis (DTA), the temperature difference that develops 
between a sample and an inert reference material is measured, when both are 
subjected to identical heat treatments. The related technique of differential 
scanning calorimetry (DSC) relies on differences in energy required to maintain the 
sample and reference at an identical temperature (Ford and Timmins, 1989). 
1.3.2 Differential Scanning Calorimetry (DSC) 
In thermal analysis, differential scanning calorimetry (DSC) and differential thennal 
analysis (DTA) are the most important methods. Both DSC and DTA may detect 
the enthalpy changes, which occur in a sample as it is heated or cooled under fixed 
conditions. DSC is often considered to be more evolved than DTA, as DSC is able 
to provide quantitative and qualitative data (Ford and Timmins, 1989). 
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1.3.3 Principles of DSC 
There are two types of DSC systems in common use, namely the power 
compensation and the heat flux DSCs (Griffin and Laye, 1992). In power 
compensation DSC the temperatures of the sample and reference are controlled 
independently using separate, identical furnaces. The temperatures of the sample 
and reference are made identical by varying the power input to the two furnaces; 
the energy required to do this is a measure of the enthalpy or heat capacity 
changes in the sample relative to the reference. 
In heat flux DSC, the sample and reference are connected by a low resistance heat 
flow path (a metal disc). The assembly is enclosed in a single furnace. Enthalpy or 
heat capacity changes in the sample cause difference in its temperature relative to 
the reference; the resulting heat flow is small compared with that in differential 
thermal analysis (DTA) because the sample and reference are in good thermal 
contact. The temperature difference is recorded and related to enthalpy change in 
the sample using calibration experiments. The differential temperature is converted 
into heat flow using the equation below (Haines eta/., 1998). 
Equation 1. 1 
Where Q is heat (J), tis time (s), Rr is the thermal resistance of the cell (Kw-1), Ts 
is the temperature of the sample (K) and Tr is the temperature of the reference (K). 
Figure 1.1 shows the most popular DSC design. Two pans are placed on a pair of 
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Figure 1.1. The design of Perkin Elmer Differential Scanning Calorimeter Pyris 6 
(Perkin Elmer Ltd, UK) 
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identically positioned platforms connected to a furnace pan by a common heat flow 
bath. The polymer sample is placed in one pan, whereas the reference sample is 
placed in the other pan. The connection ,of computer into the furnace is utilized in 
order to turn the furnace on and also to monitor the heat of two pans at a specific 
rate. 
1.3.4 Application of DSC 
DSC is the most widely used of all thermo-analytical techniques. It is used primarily 
to characterize polymers and organic materials, as well as metals, ceramics, and 
composites. Basically the DSC measurement is a function of differential heat flow 
. with temperature for compounds that exhibit thermal transitions. These transitions 
are typically melting, crystallization, and the glass transition (T9). Such 
measurements provide quantitative and qualitative information about physical and 
chemical changes that involve endothermic or exothermic processes. DSC has 
proven to be a power tool in elucidating as to whether a drug and its carrier may 
interact when fused together or may be stable (Dordunoo et a/., 1996), and so, 
facilitates the selection of a formulation that consists of the optimal drug carrier 
ratio (Mura eta/., 1995; Mooter eta/., 1998). 
Figure 1.2 shows a typical scan for a polymer. When DSC starts heating the two 
pans, the computer plotting the heat absorbed by the polymer against temperature, 
initially by straight line. When polymer is heated a little more, after a certain 
temperature, plot will shift upward· suddenly, this happens because the polymer 
has just gone through the glass transition. At this point, the heat is being absorbed 
18 
the samples and there is an increase in the heat capacity of the sample during 
process. The crystallization temperature (T c) is reached when the polymer 
. sample has gained enough energy to moye into an ordered arrangement of crystal. 
When the molecules of the polymer fall into these crystalline arrangements, they 
;: give off heat, which is detected as exothermic peak in the plot of heat flow versus 
.. temperature. The melting temperature (T m) is reached when the polymer 
undergoes an endothermic thermal transition, which is called the melting 
temperature. When T m is reached, the temperature of the polymer will not rise until 
all the crystals have melted. 
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Figure 1.2 A possible DSC thermal profile during thermal processes (Ford and 
Timmins, 1989) 
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1.4 Mechanical properties 
Mechanical properties occur as a result of the physical properties inherent to each 
material, and are determined through a series of standardized mechanical tests, 
such as tensile strength and elongations which can be measured to evaluate the 
mm properties. Tensile strength tells about how much stress is needed to break the 
mm sample, but it does not tell anything about what happens to film sample while 
:rying to break it, therefore that is the reason why it is important to study the 
~longation behavior of polymer sample. These properties are important 
:haracteristics to predict the stability and release property of film coated dosage 
=orms (Sakellariou et a/., 1985; Johnson eta/., 1991; Parikh eta/., 1993; Obara and 
111cGinity, 1994; Baie and Sarwar, 1995). 
1.5 Permeability Studies 
)ince the drug release from a coated dosage form depends upon the porosity of 
he membrane, permeability studies were conducted to provide useful information 
egarding the potential effects of the permeability of the film (Wang, 1994). Several 
;tudies have been performed on permeability properties for enteric films (Parker et 
1/., 1974; Spiteal and Kinget, 1980; Guo eta/., 1993; Saettone eta/., 1995). All of 
he above studies used the same design of the transmission cell. It consisted of a 
;crew-capped, cylindrical glass bottle with a circular hole in the screw cap. A 
:ircular piece of film was placed between two rubber gaskets, which were then 
ixed inside the screw cap. The bottle contained moisture absorbent material, 
1laced in controlled relative humidity environment. 
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6 FTIR - Introduction 
ourier Transform Infrared (FTIR) spectroscopy is a powerful analytical tool for 
1aracterizing and identifying organic molecules. Using the IR spectrum, chemical 
onds and the molecular structure of organic compounds can be identified. FTIR is 
te preferred method of infrared spectroscopy. In infrared spectroscopy, IR 
ldiation is passed through a sample. Some of the infrared radiation is absorbed 
y the sample and some of it is passed through (transmitted). The resulting 
pectrum represents the molecular absorption and transmission, creating a 
1olecular fingerprint of the sample. Like a fingerprint, no two unique molecular 
tructures produce the same infrared spectrum. This makes infrared spectroscopy 
seful for several types of analysis. 
TIR is most useful for identifying chemicals that are either organic or inorganic 
Bell, 1972). FTIR can be used to identify chemicals from spills, paints, polymers, 
:oatings, drugs, and contaminants. Therefore, FTIR is a rapid technique that is 
·ery efficient in industrial applications, such as weathering (Nagai eta/., 1997) or 
tnalysis of blends (Fischer eta/., 1997) and to study the interactions between the 
lrug and the polymer blends. FTIR is perhaps the most powerful tool for the 
:ientification of the interaction between the polymer and the drug blends at the 
nolecular level, which allows a comparative investigation of drug performance, in 
he solid state, either when mixed with the required excipients in the formulation of 
he matrix tablets or in other pharmaceutical dosage forms. The idea of using an 
=TtR to study drug-polymer blends is that it can provide valuable information 
·egarding the interactions of drug-polymer blends, which cause changes in the 
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,ration dipole of the molecules. This will appear as changes in the frequency and 
ndwidth of interacting groups in the spectrum (Nair eta/., 2001; Eerikainen eta/., 
,04; Vueba eta/., 2006). 
te term Fourier Transform Infrared Spectroscopy (FTIR) refers to a fairly recent 
!Velopment in the manner in which the data is collected and converted from an 
.erference pattern to a spectrum. Today's FTIR instruments are computerized 
tich makes them faster and more sensitive than the older dispersive instruments 
wing, 1985). 
7 Ethylcellulose 
hylcellulose is one of the most widely used water insoluble hydrophobic polymer, 
::an be applied either as an organic solution or as an aqueous colloidal dispersion 
seudolatex). Ethylcellulose is essentially tasteless, odorless, colorless, 
1ncaloric and physiologically inert (Donbrow and Friedman, 1974; Spiteal and 
nget, 1980; lyer eta/., 1990). Ethylcellulose contains 44 to 51% of ethoxy groups 
anufactured by the reaction of ethyl chloride or ethyl sulfate with cellulose 
;solved in hydroxide Depending on the degree of ethoxy substitution, different 
;cosity grades are obtained and available. This material is completely insoluble in 
:tter and gastrointestinal fluids, and thus cannot be used alone for tablet coating. 
is usually combined with water soluble additives, such as hydroxypropyl 
ethylcellulose, to prepare films with reduced water solubility properties (Lachman 
a/., 1986; Sadeghi eta/., 2000). 
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Ethylcellulose has been extensively used as a pharmaceutical vehicle in a number 
of dosage forms. It has a long history of use in the pharmaceutical field as a coat to 
various forms, including tablets, granules and powders (Donbrow and Friedman, 
1974; Palmieri and Wehrle, 1997; Lin eta/., 2001; Ymada eta/., 2001), as a tablet 
binder (Chowhan, 1980), in the preparation of microcapsules and microspheres 
(Bodmeier and Chen, 1989), and also as film and matrices forming material for 
sustained release dosage forms (Shaikh eta/., 1987; Shlieout and Zessin, 1996; 
Pather eta/., 1998). The permeability of ethylcellulose membrane can be increased 
by the addition of water soluble materials such as PEG 400 as plasticizer (Wood 
and Syarto, 1964) and polyvinylpyrrolidone {PVP). 
However, ethylcellulose shows some major disadvantages, which have a negative 
influence on the production time such as significant curing effects. Therefore, to 
accelerate the film formation process and avoid stability problems a curing step 
(thermal treatment) at elevated temperatures above the minimum film formation 
temperature (MFT) directly after the coating process has been recommended 
(Gilligan and Li Wan, 1991; Hutchings eta/., 1994). 
1.8 Gelucires 
Gelucires are solid waxy materials, which are the saturated polyglycolized 
~lycerides consisting of mono-, di-, and tri-glycerides and mono-, di-fatty acid 
~sters of polyethylene glycol (Baykara and Yuksel, 1991; Gattefosse, 1999; 
licente, 2000). They are derived from natural products such as olive oil, cotton 
~eed oil, sunflower oil and palm oil. Gelucires have very wide applicability in the 
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